Liraglutide
FDA approved · RxGLP-1 receptor agonist
Also known as: Victoza, Saxenda
FDA approved and prescription only. Sold as Victoza (type 2 diabetes) and Saxenda (weight management). The first GLP-1 approved for weight (2014).
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 515 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: real but more modest weight loss (roughly 5 to 8%) and blood-sugar control in human trials. Now outperformed by semaglutide and tirzepatide, and it requires daily injection.
What it is
A GLP-1 receptor agonist, the earlier-generation version of the mechanism used by semaglutide.
What the research says
Approved as Saxenda in 2014; the first GLP-1 approved specifically for weight.
Approved as Victoza for glycaemic control.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Liraglutide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Liraglutide is the intervention being tested.
Safety and Efficacy of Liraglutide in Parkinson's Disease
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
Phase and status counts reflect the 100 most recent studies; the registered total above is exact.
FDA recalls & enforcement
Live from openFDA. Times the FDA required a Liraglutide product to be pulled from the market, with the stated reason. A recall is a specific batch or manufacturing action, not a verdict on the compound itself.
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Recalled by Novo Nordisk Inc
Presence of particulate matter: a white thread-like structure in the cartridge
Recalled by Lupin Pharmaceuticals Inc.
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Recalled by Novo Nordisk Inc
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Recalled by Novo Nordisk Inc
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- GI side effects, similar to other GLP-1 drugs.
- Daily injection is less convenient than weekly options.
- Prescription medicine: not for unsupervised use.
Doses reported in studies & protocols
Approved schedules escalate under a prescriber. This is not a recommendation.
Purity reality
Only pharmacy-dispensed product has a verified supply chain.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.